Abbott Laboratories Nears Completion of Major Strategic Acquisition
Published on 03/22/2026 at 07:28 | Redaktion boerse-global.de
The healthcare giant Abbott Laboratories is on the verge of finalizing a significant strategic acquisition, following months of preparation. The official integration of Exact Sciences is scheduled for completion tomorrow, Monday. This move solidifies the corporation's standing in the diagnostics market and marks the successful conclusion of the regulatory review process.
Market Reaction and Analyst Outlook
Despite the strategic importance of the deal, the market's response has been muted. Shares closed on Friday at 91.40 euros, trading approximately 15 percent below their long-term 200-day moving average. Since the start of the year, the stock has declined by about 13.8 percent.
Market observers, however, view this acquisition as a crucial enhancement to Abbott's existing healthcare infrastructure. Analysts largely maintain their buy recommendations, with the consensus average price target standing at $139.48. The focus now shifts to the operational phase, which begins with the formal completion of the takeover set for March 23. Management's primary challenge will be the swift incorporation of the new business units into Abbott's established framework to realize the anticipated synergy effects in the diagnostics segment promptly.
Should investors sell immediately? Or is it worth buying Abbott Laboratories?
Regulatory Hurdles Cleared
The final regulatory approval was granted last Thursday, removing the last obstacle to the merger. The two companies had initially agreed to the transaction in November 2025. Shareholders provided their approval in February of this year, leaving only the necessary regulatory consents for the acquisition of the company valued at nearly $19.8 billion.
Ad
Abbott Laboratories Stock: New Analysis - 22 March
Fresh Abbott Laboratories information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
